Posted on 16 December 2014
Annexon Bioscience has closed a $34 million Series A-1 to support the development of its lead candidate, ANX005, for the treatment of neurodegenerative and autoimmune disorders.
|Searching for more deal information? Current Partnering offers the following options:|
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
The round was led by Novartis Venture Funds with participating investors Satter Investment Management, and Clarus Ventures.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
Browse: Complete Current Partnering report catalog